Your session is about to expire
← Back to Search
Rimegepant for Migraine Prevention
Study Summary
This trial will compare the migraine-preventing effects of two different doses of rimegepant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant.My migraines started before I turned 50.My migraines last between 4 to 72 hours without treatment.I stopped taking my migraine medication at least 6 months ago.My migraines started before I turned 50.My migraines last between 4 to 72 hours without treatment.I have been taking painkillers like NSAIDs or acetaminophen almost every day for the last 3 months.I've used migraine medication for other reasons almost daily for the last 3 months.I haven't taken migraine prevention medication in the last 30 days.I have had migraines for at least a year, as per the headache classification.I am not pregnant or breastfeeding.I have had 4-14 migraine attacks each month for the last 3 months.I have had 4-14 migraine attacks each month for the last 3 months.I am not taking any medications that are not allowed in this study.
- Group 1: Placebo comparator dosing
- Group 2: Rimegepant 75mg Orally Disitegrating Tablet (ODT)daily dosing
- Group 3: Rimegepant 75mg Orally Disintegrating Tablet (ODT)every other day dosing
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals can take part in this research initiative?
"Affirmative. According to clinicaltrials.gov, the medical experiment was first published on March 4th 2022 and has had its most recent update on November 2nd 2022. Moreover, 660 participants are required for this study which is being conducted at 37 distinct venues."
What potential hazards exist with a daily dosage of Rimegepant 75mg?
"With the Rimegepant 75mg daily dosing receiving a score of 3, our team at Power understands it is safe due to this being a Phase 4 trial and thus already approved for use."
Is access to this medical experiment available presently?
"According to the official clinicaltrials.gov website, this trial is actively recruiting participants and was initially posted on March 4th 2022 with its last amendment being done on November 2nd 2022."
What is the current geographic scope of this clinical trial?
"The current trail is running at 37 distinct sites, including nearby locations such as Stouffville, Gurnee and East Greenwich. To minimize travel obligations for participants, it can be advantageous to choose the closest trial site to you when enrolling."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger